Eftilagimod alpha

HR+/HER2- Breast Cancer Disease Market Analysis Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Health, Oncology, PI3K, Progesterone, PARP, Everolimus, Neutropenia, AIPAC, Fulvestrant, Sacituzumab govitecan, PALLAS, Roche, Eftilagimod alpha, HR, Ribociclib, Abemaciclib, Nausea, Breast cancer, Hyperglycemia, Population, Probability, Breast, Patient, Guideline, CHMP, Diarrhea, OS, Patent, Birth control, Pharmaceutical industry, EU, Phase, Alpelisib, Palbociclib

The "Disease Analysis: HR+/HER2- Breast Cancer" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HR+/HER2- Breast Cancer" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
  • The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.
  • By 2027, incident and prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

Retrieved on: 
Thursday, August 5, 2021
Calendar, TRADD, Australian Securities Exchange, CSO, Patient, IMM, CMO, Autoimmune disease, Pemetrexed, Cancer, Carboplatin, Eftilagimod alpha, Immunotherapy, Institute, Research, Safety, Nasdaq, GLOBE, Pharmaceutical industry

This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immuteps lead product candidate eftilagimod alpha (efti or IMP321).

Key Points: 
  • This patient with metastatic non-small cell lung carcinoma received pembrolizumab plus doublet chemotherapy (carboplatin and pemetrexed) combined with Immuteps lead product candidate eftilagimod alpha (efti or IMP321).
  • INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy and anti-PD-1 therapy.
  • CSO and CMO Dr. Frdric Triebel said: INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered.
  • We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity.

Immutep Quarterly Activities Report

Retrieved on: 
Tuesday, July 13, 2021
Immutep, LAG3, Eftilagimod alpha, Medicine

In the past quarter Immutep has entered a new phase as a biotech company at the forefront of the LAG-3 immunotherapeutic landscape.

Key Points: 
  • In the past quarter Immutep has entered a new phase as a biotech company at the forefront of the LAG-3 immunotherapeutic landscape.
  • Manufacturing scale up of efti to potential commercial quantities is progressing well, said Marc Voigt, CEO of Immutep.
  • The trial is on track to report final overall survival (OS) data in H2 of calendar year 2021.
  • Immutep previously reported OS data from approximately 60% of events in Dec 2020.

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

Retrieved on: 
Tuesday, July 6, 2021
Health, Medicine, Oncology, Immutep, Head and neck cancer, Squamous cell carcinoma, Clinical trial, Eftilagimod alpha

Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021.

Key Points: 
  • Immutep was granted Fast Track designation for efti to treat 1st line HNSCC patients by the US FDA in early April 2021.
  • Pending approval by the European and Australian competent authorities and ethics committees, Immutep expects to broaden its recruitment sites into these regions.
  • We look forward to deepening these results with a larger group of 1st line HNSCC patients in TACTI-003.
  • TACTI-003 is a Phase IIb clinical trial in 1st line Head and Neck Squamous Cell Carcinoma (HNSCC).

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

Retrieved on: 
Monday, June 21, 2021
Clinical medicine, Medicine, Cancer, Cancer treatments, Antineoplastic drugs, Immutep, Chemotherapy, Eftilagimod alpha

INSIGHT-003 will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt.

Key Points: 
  • INSIGHT-003 will be an investigator-initiated trial conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt.
  • Patients will receive 30 mg doses of efti every two weeks for 24 weeks in conjunction with standard of care chemotherapy plus anti-PD-1 therapy.
  • Thereafter, patients will enter a maintenance phase and receive either efti alone or in double or continued triple combination with anti-PD-1 therapy.
  • Commenting on the new trial, Immutep CEO Marc Voigt said: Testing efti as part of a triple combination therapy is an important and exciting expansion of our development program.

Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting

Retrieved on: 
Monday, June 7, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Drugs, Orphan drugs, Breakthrough therapy, Cancer immunotherapy, Antineoplastic drugs, Pembrolizumab, Eftilagimod alpha

Previously, Seven and Eight Biopharma reported that intravenous administration of BDB001 as monotherapy showed favorable tolerability and robust systemic immune activation leading to durable clinical responses.

Key Points: 
  • Previously, Seven and Eight Biopharma reported that intravenous administration of BDB001 as monotherapy showed favorable tolerability and robust systemic immune activation leading to durable clinical responses.
  • The poster discussion session at ASCO for Abstract #2512 revealed new interim safety and efficacy results for a Phase 1 dose escalation / expansion trial of BDB001 in combination with pembrolizumab in advanced solid tumors (NCT03486301).
  • The results show that BDB001 in combination with pembrolizumab was well tolerated, and induced robust immune activation leading to clinical responses.
  • These promising interim results show that BDB001 in combination with pembrolizumab represents a novel and viable treatment for advanced solid tumors.

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

Retrieved on: 
Tuesday, June 1, 2021
Clusters of differentiation, LAG3, Immutep, Eftilagimod alpha

Bintrafusp alfa aims to block two immunosuppressive pathways, TGF- and PD-L1, while efti activates antigen presenting cells, via the LAG-3 MHC II pathway.

Key Points: 
  • Bintrafusp alfa aims to block two immunosuppressive pathways, TGF- and PD-L1, while efti activates antigen presenting cells, via the LAG-3 MHC II pathway.
  • The new trial builds on our knowledge and the encouraging data from the INSIGHT trial of efti, also in solid tumours.
  • We are very pleased to be expanding our involvement with Immutep to explore efti in a new combination with bintrafusp alfa.
  • Immutep is financially supporting the trial to be run by IKF, and Merck, Darmstadt, Germany is financially contributing to the biomarker-related work.

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

Retrieved on: 
Wednesday, May 26, 2021
Chemistry, Chemical compounds, Physical sciences, Ammine complexes, Immutep, Eftilagimod alpha, Cancer treatments, Oxaliplatin, Chemotherapy, LAG3, Carboplatin, Patent attorney

This Chinese patent follows the grant of the corresponding European, Australian, Japanese and United States patents, as announced separately throughout 2019 and 2020.

Key Points: 
  • This Chinese patent follows the grant of the corresponding European, Australian, Japanese and United States patents, as announced separately throughout 2019 and 2020.
  • The new patent protects Immuteps intellectual property relating to combination therapy comprising (a) lead active immunotherapy candidate eftilagimod alpha (efti or IMP321), which is a LAG-3 fusion protein (LAG-3Ig), and (b) a chemotherapy agent.
  • The chemotherapy agent is oxaliplatin, carboplatin, or topotecan, and the patent provides protection in the territory of mainland China.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep To Present At The Jefferies Virtual Healthcare Conference

Retrieved on: 
Tuesday, May 25, 2021
Immutep, LAG3, Autoimmune disease, Medicine, Health, Eftilagimod alpha

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.

Key Points: 
  • Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease.
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
  • Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Immutep Operational Update

Retrieved on: 
Friday, May 7, 2021
Immutep, LAG3, Biotechnology, Monoclonal antibodies, Eftilagimod alpha, Health care

Currently the trial has reached approximately 72% of events, indicating 72% of total patients with this late-stage cancer had been followed through until death.

Key Points: 
  • Currently the trial has reached approximately 72% of events, indicating 72% of total patients with this late-stage cancer had been followed through until death.
  • Currently, 27 patients of a total of 36 patients have received the first treatment.
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.